You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
AutoRegister: A system for enhancing the accuracy of tumor change detection
SBC: CORTICOMETRICS LLC Topic: 102PROJECT SUMMARY This project proposes to continue the development of AutoRegisterTMan integrated software based system for enhancing the accuracy of tumor change detectionThe intent of the system is to automate the alignment of a patient s brain scan with that of a prior scan such that subsequent offline tumor measurements do not have error introduced solely by differing slice orientationsWhile si ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Lead Compound Discovery from Engineered Analogs of Occidiofungin
SBC: Sano Chemicals, Inc. Topic: NIAIDProject Summary Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have also revealed that occi ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy
SBC: CBS THERAPEUTICS, INC. Topic: 102ABSTRACT Recent studies of the applicants support the role of the endogenous gaseous biological mediator hydrogen sulfide H S in colorectal cancer In specific the selective upregulation of cystathionine synthase CBS and the subsequent production of H S in colonic cancer cells serves as a pro survival factor by stimulating tumor cell bioenergetics ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Microparticulate mucosal vaccine for triple-negative breast cancer
SBC: KIROMIC BIOPHARMA INC Topic: 103ABSTRACT Triple negative breast cancerTNBCis a molecular subtype of breast cancer that is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptorHERClinicallyit is characterized by aggressive behaviordistinct patterns of metastasisand high rates of recurrence and mortalitySince TNBC tumor cells lack the necessary receptorsthe disease does not respo ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Aspirin-PC for Chemoprevention of Colorectal Cancer
SBC: PLx Opco Inc. Topic: NCIABSTRACT Colorectal cancerCRCis the third leading cause of cancer related deaths in the U SBased on numerous epidemiological studies and recent prospective clinical trialsthe use of daily aspirin is associated with a significant reduction in CRC incidencedeaths and metastatic spreadHoweverthe chronic use of this drug is limited due to the side effects of gastrointestinal bleeding ulceration in sus ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Oral Small Molecule STAT Inhibitor to Treat Cachexia in Chronic Kidney Disease
SBC: StemMed, Ltd. Topic: 400DESCRIPTION provided by applicant Chronic kidney disease CKD is a major public health problem in the US with an estimated prevalence of million patients enter hemodialysis or peritoneal dialysis programs yearly A serious complication in of patients with CKD is cachexia or muscle wasting which decreases quality of life and increases morbidity and mortality Unfortunately ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Targeting Synaptotagmin to Prevent Airway Mucus Obstruction
SBC: Exotect, LLC Topic: NHLBIPROJECT SUMMARY Mucus dysfunction underlies the pathophysiology of a number of common respiratory diseases including asthma cystic fibrosis and chronic obstructive pulmonary disease COPD Asthma alone impacts of the US population resulting in considerable cost morbidity and occasional mortality caused by mucus hypersecretion Recently it was discovered that Synaptotagmin Syt regul ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development Characterization and Commercialization of a Viably Frozen Patient Inclusive Hepatocellular Carcinoma Tumor Bank
SBC: Woodland Pharmaceuticals LLC Topic: 103Abstract Hepatocellular carcinoma HCC is a disease of growing incidence globally including in the US by per year With the recent success of anti viral therapies the etiology of HCC in the American population is projected to shift from viral HBV HCV hepatitis to primarily fatty liver disease in the near future Currently only one effective systemic therapy has been developed for HCC ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Investigation of antibody drug conjugates of a novel target
SBC: WNTRIX INC Topic: NCIPROJECT SUMMARY Antibody drug conjugates ADCs are monoclonal antibodies mAbs that are covalently linked to cell killing drugs and have emerged as a major modality in anti cancer treatment This approach combines high specificity of mAbs against their antigen targets with highly potent cytotoxic drugs resulting in armed mAbs that deliver the payload drug to tumor cells with enriched levels ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of PAR Pepducins as a Novel Antithrombotic Treatment
SBC: OASIS PHARMACEUTICALS, LLC Topic: NHLBICoronary artery disease remains the leading cause of death in the United States Platelets play an important role in the pathogenesis of acute coronary syndrome ACS as platelet activation aggregation and secretion are key components of arterial thrombus formation Despite dual anti platelet therapy for ACS and percutaneous coronary interventions PCI many patients sustain a high incidence u ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health